Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Ingenol mebutate useful for treating actinic keratosis

28 May 2020

Ingenol mebutate is safe and effective in the treatment of patients with actinic keratosis, in addition to exerting a positive impact on quality of life, as shown in a study.

The study included 440 patients (average age, 73.5 years; 65.9 percent male) who were followed for 12 months. Researchers recorded medical history details, as well as assessed effectiveness, compliance to treatment, quality of life (EQ‐5D‐5L), and treatment satisfaction questionnaire for medication (TSQM‐9) at week 8.

Mean duration of participation in the study was 10 months. Most of the patients had skin types II (n=197; 44.8 percent) and III (n=173; 39.3 percent) according to the Fitzpatrick’s scale for skin type; 33 patients (7.3 percent) had type I, 35 (8.0 percent) had type IV, and three (0.7 percent) had type VI.

A total of 428 patients (97.3 percent) attended the 8-week assessment. Complete clearance occurred in 337 patients (78.7 percent). Additionally, EQ VAS score significantly increased from baseline (p<0.001). TSQM‐9 data showed that patients with complete clearance had significantly higher satisfaction in effectiveness, convenience, and global satisfaction.

At the 12‐month follow‐up, 323 patients (95.8 percent) retained their clearance status. The complete clearance rate was 42.1 percent in the group of 19 patients who did not apply the ingenol mebutate gel on consecutive days. In comparison, the rate was higher at 80.6 percent in the group of those used the gel on consecutive days. None of the patients developed skin cancer.

While ingenol mebutate stands out for its short treatment course and efficacy in actinic keratitis, the findings underscore that limited adherence to treatment might reduce effectiveness, the researchers said.

Editor's Recommendations
Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.